| abstract |
Disclosed herein are compounds that inhibit dual leucine zipper kinase (DLK) kinase activity (MAP3K12), pharmaceutical compositions, and methods of treating DLK-mediated diseases, such as neurological diseases resulting from injury. traumatic to the central nervous system and peripheral nervous system neurons (eg, stroke, traumatic brain injury, spinal cord injury), or resulting from a chronic neurodegenerative condition (eg, Alzheimer's disease, frontotemporal dementia, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, spinocerebellar ataxia, progressive supranuclear palsy, Lewy body disease, Kennedy disease, and other related conditions), from neuropathies resulting from neurological damage (chemotherapy-induced peripheral neuropathy, diabetic neuropathy, and related disorders) and of cognitive disorders caused p or pharmacological intervention (eg, chemotherapy-induced cognitive disorder, also known as chemobrain). |